Literature DB >> 23990522

Diabetes in first-degree family members: a predictor of type 2 diabetes in 159 nonscreening Alabama hemochromatosis probands with HFE C282Y homozygosity.

James C Barton1, J Clayborn Barton, Ronald T Acton.   

Abstract

OBJECTIVE We sought to identify predictors of diabetes diagnosed before hemochromatosis. RESEARCH DESIGN AND METHODS We studied these 16 variables in 159 nonscreening hemochromatosis probands with HFE C282Y homozygosity: age; sex; BMI; diabetes reports in first-degree family members (dichotomous); heavy ethanol consumption; cigarette smoking; elevated serum alanine aminotransferase/aspartate aminotransferase levels; nonalcoholic fatty liver; chronic viral hepatitis; cirrhosis; hand arthropathy; iron removed by phlebotomy; and positivity for HLA-A*01, B*08; A*03, B*07; and A*03, B*14 haplotypes. We performed univariable and multivariable analyses. RESULTS Twenty-three probands (14.5%) had diabetes; 19 were men. Each of the 23 probands had type 2 diabetes. Mean BMI was greater in probands with diabetes (31.7 ± 8.5 [SD] kg/m(2) vs. 27.6 ± 5.1 kg/m(2); P = 0.032). Reports of any first-degree family member with diabetes were more prevalent in probands with than in probands without diabetes (69.6 vs. 17.6%; P < 0.0001). In probands with diabetes, the odds ratio (OR) of maternal diabetes was 6.7 (95% CI 2.3-19.7; P = 0.0005) and of sibling diabetes was 11.7 (3.0-45.5; P = 0.0004). In a logistic regression model, predictors of diabetes at hemochromatosis diagnosis in 159 probands were diabetes reports in family members (OR 8.5 [95% CI 2.9-24.8]; P < 0.0001) and BMI (1.1 [1.0-1.2]; P = 0.049). This model explained 26.0% of total deviance contributing to diabetes. CONCLUSIONS In nonscreening hemochromatosis probands with HFE C282Y homozygosity, a heritable factor(s) increases the risk of diabetes diagnosed before hemochromatosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23990522     DOI: 10.2337/dc13-0713

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  HLA-A*03, the hemochromatosis ancestral haplotype, and phenotypes of referred hemochromatosis probands with HFE p.C282Y homozygosity.

Authors:  James C Barton; J Clayborn Barton; Ronald T Acton
Journal:  Hereditas       Date:  2022-06-06       Impact factor: 2.595

Review 2.  Endocrine dysfunction in hereditary hemochromatosis.

Authors:  C Pelusi; D I Gasparini; N Bianchi; R Pasquali
Journal:  J Endocrinol Invest       Date:  2016-03-07       Impact factor: 4.256

3.  Risk Factors for Insulin Resistance, Metabolic Syndrome, and Diabetes in 248 HFE C282Y Homozygotes Identified by Population Screening in the HEIRS Study.

Authors:  James C Barton; J Clayborn Barton; Paul C Adams; Ronald T Acton
Journal:  Metab Syndr Relat Disord       Date:  2016-01-15       Impact factor: 1.894

4.  Anti-obesity and pro-diabetic effects of hemochromatosis.

Authors:  Mousa Al Abbas; Deveraprabu Abraham; James P Kushner; Donald A McClain
Journal:  Obesity (Silver Spring)       Date:  2014-07-14       Impact factor: 5.002

Review 5.  Diabetes in HFE Hemochromatosis.

Authors:  James C Barton; Ronald T Acton
Journal:  J Diabetes Res       Date:  2017-02-26       Impact factor: 4.011

6.  Undiagnosed diabetes and impaired fasting glucose in HFE C282Y homozygotes and HFE wild-type controls in the HEIRS Study.

Authors:  James C Barton; J Clayborn Barton; Paul C Adams; Ronald T Acton
Journal:  BMJ Open Diabetes Res Care       Date:  2016-12-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.